CHRM2: A G Protein-Coupled Receptor and Potential Drug Target

Target Name: CHRM2

NCBI ID: G1129

CHRM2

CHRM2: A G Protein-Coupled Receptor and Potential Drug Target

CHRM2, also known as Cholinergic receptor, Muscarinic 2, or Isoform A, is a G protein-coupled receptor that is expressed in the central nervous system (CNS) and peripheral tissues. It is a member of the muscarinic receptor family, which includes several other G protein-coupled receptors, including the muscarinic receptor, M1 (D2), and the nicotinic receptor, NTR. These receptors are involved in a variety of physiological processes in the body, including neurotransmitter signaling, pain perception, and cardiovascular function.

CHRM2 is a transmembrane protein that is characterized by its long, N-terminal Extracellular domain (ECD), which is involved in the formation of a complex with other proteins, including the neurotransmitter acetylcholine. This interaction between CHRM2 and acetylcholine is critical for the function of the receptor, as it allows the receptor to transmit signals from the neurotransmitter system to the intracellular signaling pathway.

CHRM2 is involved in a variety of physiological processes in the body, including neurotransmitter signaling, pain perception, and cardiovascular function.

Neurotransmitter signaling

CHRM2 is a critical receptor for the neurotransmitter acetylcholine, which is involved in the regulation of various physiological processes in the body, including memory, attention, and micturition. When acetylcholine binds to CHRM2, it triggers a signaling cascade that involves the activation of several intracellular signaling pathways.

One of the most well-known functions of CHRM2 is its role in the regulation of memory and attention. Studies have shown that CHRM2 is involved in the formation of memory traces, which are the neural representations of previously experienced sensory information. These memory traces are critical for the consolidation and recall of memories, and for the proper functioning of the learning process.

In addition to its role in memory and attention, CHRM2 is also involved in the regulation of pain perception and cardiovascular function. Studies have shown that CHRM2 is involved in the transmission of pain signals from the nervous system to the brain, and that it plays a role in the regulation of cardiovascular function, including heart rate and blood pressure.

Muscarinic receptor antagonism

CHRM2 is also an attractive drug target for Muscarinic receptor antagonists, which are drugs that are designed to block the action of muscarinic receptors. Muscarinic receptors are involved in a variety of physiological processes in the body, including neurotransmitter signaling, pain perception, and cardiovascular function.

The use of Muscarinic receptor antagonists has been shown to be effective in treating a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and anxiety disorders. These drugs work by binding to the muscarinic receptor and inhibiting its activity.

CHRM2 as a drug target

The potential use of CHRM2 as a drug target is due to its role in the regulation of neurotransmitter signaling and its involvement in a variety of physiological processes in the body. Additionally, CHRM2 is a good candidate for Muscarinic receptor antagonism due to its high degree of homogeneity and its expression in multiple tissues and organs.

One of the potential advantages of targeting CHRM2 is its potential to have a more selective and targeted effect on muscarinic receptors than other G protein-coupled receptors. This is because CHRM2 has a unique structure that allows it to interact specifically with certain muscarinic receptors, rather than with all muscarinic receptors.

Another advantage of targeting CHRM2 is its potential to have a more prolonged effects than other Muscarinic receptor antagonists. Studies have shown that CHRM2 can have a lasting effect on neurotransmitter signaling for up to several hours after treatment, which could be useful for the treatment of chronic disorders.

Conclusion

CHRM2 is a G protein-coupled receptor that is involved in a variety of physiological processes in the body, including neurotransmitter signaling, pain perception, and cardiovascular function. Its potential as a drug target is due to its unique structure and its involvement in multiple physiological processes. Additionally, CHRM2 is a good candidate for Muscarinic receptor antagonism due to its high degree of homogeneity and its expression in multiple tissues and organs. Further research is needed to fully understand the role of CHRM2 in the regulation of neurotransmitter signaling and its potential as a drug target.

Protein Name: Cholinergic Receptor Muscarinic 2

Functions: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol

The "CHRM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHRM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets